Public Health Policies And Interventions To Reduce Tobacco-related Harms Among Socially Disadvantaged Populations And ‘low Probability Quitters’
Funder
National Health and Medical Research Council
Funding Amount
$421,747.00
Summary
Tobacco continues to be a leading cause of preventable death and disease in Australia. Those who are socially disadvantaged are at higher risk of smoking, which contributes to the health gap between the rich and poor. This research will provide evidence for policy makers on interventions which could reduce smoking among the most disadvantaged in society. It will also examine whether less harmful nicotine products could a reduce health risks in smokers who find quitting difficult.
Progressing Life Course Research In Psychiatric Epidemiology
Funder
National Health and Medical Research Council
Funding Amount
$331,674.00
Summary
Mental health and alcohol disorders are major public health problems which cause long-term disabilities, poor health and early mortality. Addressing these problems requires a better understanding of the early factors leading to these disorders. This research program represents a unique opportunity to increase our knowledge of the origins of these disorders and significantly contribute to improved mental health and alcohol prevention policies and programs.
Increasing Global And National Knowledge About Illicit Drug Use, Harms And Effective Interventions
Funder
National Health and Medical Research Council
Funding Amount
$431,000.00
Summary
This Fellowship aims to increase global and national knowledge about drug use and related harms, and interventions to prevent harm and improve public health. It will create new knowledge that will be used by UN and international agencies, and national governments, to monitor changes in drug use and harms, and guide policy and planning for drug treatment and harm reduction services.
Dependent drug use is associated with a range of physical and mental health problems. However the process by which drug-related changes to the human brain influence behaviours important to remaining abstinent is poorly understood. The current proposal investigates the neural and behavioural effects of drug dependence on cognitive control - responsible for impulse control and decision making - previously implicated in drug dependence.
The Hunt For New-generation Lipopeptide Antibiotics Targeting Gram-negative ‘Superbugs’
Funder
National Health and Medical Research Council
Funding Amount
$473,477.00
Summary
The dry antibiotic discovery and development pipeline, together with the increasing incidence of bacterial resistance in the clinic has been dubbed ‘the perfect storm’. This project involves the design, synthesis and preclinical evaluation of a new generation of polymyxin-like lipopeptides that have low nephrotoxicity and specifically target polymyxin-resistant Gram-negative ‘superbugs’.
Dissecting The Interactions Of Antimalarial Drugs With The Two Key Determinants Of Drug Resistance In The Malaria Parasite - The 'chloroquine Resistance Transporter' And The 'multidrug Resistance Transporter 1'
Funder
National Health and Medical Research Council
Funding Amount
$415,218.00
Summary
The malaria parasite is a single-celled organism which invades the red blood cells of its host. The aim of this fellowship is to study two proteins that are central to the parasite’s ability to evade the toxic effects of a number of drugs. The parasite's susceptibility to chloroquine, and other drugs, is altered by small changes in these proteins. This work will advance our understanding of the increasingly widespread phenomenon of antimalarial drug resistance, and of how it may be overcome.
Determining The Bacterial Contributions To Tuberculosis And Identification Of Drug Targets
Funder
National Health and Medical Research Council
Funding Amount
$443,946.00
Summary
Serious issues of drug resistance have emerged in tuberculosis prevention and are placing enormous pressure on global health systems. We have identified an enzyme of M. tuberculosis that is essential for its survival. This project will develop potent inhibitory compounds for this enzyme. Further, we will identify new drug targets through a screen to specifically identify the genes of the organism essential for its survival in the body. This information will be used to develop new TB drugs.